Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926613 | 0.92 | KDM4E (0.57) | KDM4EALDH1A1ABCG2GAAPPARG | |
| SCHEMBL926258 | 0.90 | CYP19A1 (0.47) | KDM4EALDH1A1ABCG2GAACYP11B1 | |
| SCHEMBL925244 | 0.86 | NPC1 (0.48) | KDM4EALDH1A1ABCG2GAAKMT2A | |
| SCHEMBL1082928 | 0.85 | MAPT (0.53) | KDM4EALDH1A1KMT2AHSD17B10 | |
| SCHEMBL3703832 | 0.85 | CYP11B1 (0.47) | KDM4EALDH1A1ABCG2CYP11B1CYP11B2 | |
| SCHEMBL928086 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1ABCG2GAAPPARG | |
| SCHEMBL5126203 | 0.82 | MAPT (0.56) | KDM4EALDH1A1ABCG2CYP11B1CYP11B2 | |
| SCHEMBL29167450 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1ABCG2GAAPPARG | |
| SCHEMBL15231797 | 0.82 | KDM4E (0.62) | KDM4EALDH1A1ABCG2GAAPPARG | |
| Hydrochloric Acid SCHEMBL928010 | 0.82 | PPARG (0.40) | KDM4EALDH1A1ABCG2GAAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| EP-2268628-B1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| EP-2268628-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | Rottapharm S.p.A. (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009109230-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | NAT1, AADAC, OPRL1 | KDM4E 3085/4885ALDH1A1 401/4885ABCG2 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.